{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:52Z","timestamp":1786988152926,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejps.2025.107135","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T11:23:21Z","timestamp":1747826601000},"page":"107135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["NDMA in macrolides: GC-MS\/MS method for its detection and study of its formation"],"prefix":"10.1016","volume":"211","author":[{"given":"Nejc","family":"Golob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Grahek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-9117","authenticated-orcid":false,"given":"Robert","family":"Ro\u0161kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejps.2025.107135_bib0001","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/cpb.c20-00431","article-title":"Temperature-dependent formation of N-Nitrosodimethylamine during the storage of ranitidine reagent powders and tablets","volume":"68","author":"Abe","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"10.1016\/j.ejps.2025.107135_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105355","article-title":"A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products","volume":"139","author":"Akkaraju","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107135_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113582","article-title":"HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products","volume":"191","author":"Alshehri","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.ejps.2025.107135_bib0004","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.jmedchem.0c02120","article-title":"Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities","volume":"64","author":"Bharate","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107135_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115003","article-title":"Evaluation and optimization of a HS-SPME-assisted GC-MS\/MS method for monitoring nitrosamine impurities in diverse pharmaceuticals","volume":"221","author":"Chang","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.ejps.2025.107135_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","article-title":"Nitroso Impurities in Drug Products: an Overview of Risk Assessment, Regulatory Milieu, and Control Strategy","volume":"24","author":"Charoo","year":"2023","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"10.1016\/j.ejps.2025.107135_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.chroma.2016.06.064","article-title":"Determination of 15 N-nitrosodimethylamine precursors in different water matrices by automated on-line solid-phase extraction ultra-high-performance-liquid chromatography tandem mass spectrometry","volume":"1458","author":"Farre","year":"2016","journal-title":"J. Chromatogr. A."},{"key":"10.1016\/j.ejps.2025.107135_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106026","article-title":"NDMA analytics in metformin products: comparison of methods and pitfalls","volume":"168","author":"Fritzsche","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2025.107135_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0928-0987(02)00087-8","article-title":"Characterization of azithromycin hydrates","volume":"16","author":"Gandhi","year":"2002","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107135_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121687","article-title":"Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products","volume":"618","author":"Golob","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2025.107135_bib0018","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.xphs.2023.03.007","article-title":"NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product","volume":"112","author":"Golob","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2025.107135_bib0019","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","article-title":"Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals","volume":"112","author":"Horne","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2025.107135_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.38212\/2224-6614.3400","article-title":"A substructure-based screening approach to uncover N-nitrosamines in drug substances","volume":"30","author":"Kao","year":"2022","journal-title":"J. Food Drug Anal."},{"issue":"12","key":"10.1016\/j.ejps.2025.107135_bib0021","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1021\/acs.oprd.0c00462","article-title":"Ranitidine\u2014Investigations into the Root Cause for the Presence of N-Nitroso-N,N-dimethylamine in Ranitidine Hydrochloride Drug Substances and Associated Drug Products","volume":"24","author":"King","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejps.2025.107135_bib0022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.chemosphere.2016.08.070","article-title":"Veterinary antibiotics used in animal agriculture as NDMA precursors","volume":"164","author":"Leavey-Roback","year":"2016","journal-title":"Chemosphere"},{"issue":"18","key":"10.1016\/j.ejps.2025.107135_bib0023","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.3390\/ijerph18189465","article-title":"Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications","volume":"18","author":"Li","year":"2021","journal-title":"Int. J. Environ. Res. Public Health."},{"key":"10.1016\/j.ejps.2025.107135_bib0024","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2025.107135_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2024.114498","article-title":"Risk characterization of N-nitrosodimethylamine in pharmaceuticals","volume":"186","author":"Paustenbach","year":"2024","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejps.2025.107135_bib0026","article-title":"A robust analytical method for simultaneous quantification of 13 low-molecular-weight N-Nitrosamines in various pharmaceuticals based on solid phase extraction and liquid chromatography coupled to high-resolution mass spectrometry","volume":"192","author":"Planin\u0161ek","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107135_bib0027","article-title":"A comprehensive approach for N-nitrosamine determination in pharmaceuticals using a novel HILIC-based solid phase extraction and LC-HRMS","volume":"282","author":"Planin\u0161ek","year":"2025","journal-title":"Talanta"},{"key":"10.1016\/j.ejps.2025.107135_bib0014","unstructured":"FDA, 2023. Guidance for Industry Control of Nitrosamine Impurities in Human Drugs. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Available on: https:\/\/www.fda.gov\/media\/170794\/download. Accessed January 23, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0013","unstructured":"FDA, 2021. Guidance for Industry Control of Nitrosamine Impurities in Human Drugs. Available on: https:\/\/www.fda.gov\/media\/141720\/download. Accessed January 17, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0012","unstructured":"FDA, 2019. Combined Direct Injection N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS\/MS. Available on: https:\/\/www.fda.gov\/media\/123409\/download. Accessed February 5, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0010","unstructured":"EMA, 2021. Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products, EMA\/409815\/2020. Available on: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders\/applicants-chmp-opinion-article-53-regulation-ec-no-726\/2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf. Accessed January 20, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0007","unstructured":"EDQM, 2020. Ph. Eur. Commission adopts a new general chapter for the analysis of N-nitrosamine impurities. Available on: https:\/\/www.edqm.eu\/en\/news\/ph-eur-commission-adopts-new-general-chapter-analysis-n-nitrosamine-impurities. Accessed February 4, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0028","unstructured":"Rengaraju, S. (inventor), 2002. Process for the preparation of non-hygroscopic azithromycin dihydrate. U.S. Patent 2002\/0111318 A1."},{"key":"10.1016\/j.ejps.2025.107135_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.watres.2020.115682","article-title":"Monitoring NDMA precursors throughout membrane-based advanced wastewater treatment processes by organic matter fluorescence","volume":"175","author":"Roccaro","year":"2020","journal-title":"Water Res"},{"issue":"620","key":"10.1016\/j.ejps.2025.107135_bib0030","article-title":"Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite","volume":"25","author":"Schlingemann","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejps.2025.107135_bib0031","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107135_bib0032","article-title":"Prevalence of nitrosamine contaminants in drug samples: has the crisis been overcome?","author":"Schmidtsdorff","year":"2022","journal-title":"Arch. Pharm."},{"issue":"4","key":"10.1016\/j.ejps.2025.107135_bib0033","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202100435","article-title":"Risk assessment for nitrosated pharmaceuticals: a future perspective in drug development","volume":"355","author":"Schmidtsdorff","year":"2022","journal-title":"Arch. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2025.107135_bib0037","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","article-title":"An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals","volume":"31","author":"Wichitnithad","year":"2023","journal-title":"Saudi Pharm. J."},{"issue":"4","key":"10.1016\/j.ejps.2025.107135_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1208\/s12248-020-00473-w","article-title":"A Cautionary Tale: quantitative LC-HRMS Analytical Procedures for the Analysis of N-Nitrosodimethylamine in Metformin","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J"},{"issue":"10","key":"10.1016\/j.ejps.2025.107135_bib0039","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.xphs.2023.07.022","article-title":"Performance Characteristics of Mass Spectrometry-Based Analytical Procedures for Quantitation of Nitrosamines in Pharmaceuticals: insights from an Inter-laboratory Study","volume":"112","author":"Yang","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107135_bib0036","unstructured":"USP, 2022. Nitrosamine Impurities. Available on: https:\/\/www.usp.org\/impurities\/nitrosamine-impurities. Accessed February 11, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0035","unstructured":"USP, 2021. Testing Methods for N-Nitrosamines Monitoring in Pharmaceuticals. Available on: https:\/\/www.ipa-india.org\/wp-content\/uploads\/2023\/03\/session-4-dr-mrunal-jaywant.pdf. Accessed February 22, 2025."},{"key":"10.1016\/j.ejps.2025.107135_bib0034","unstructured":"USP, 2019. Overview of Testing Methods for N-nitrosamines Monitoring: regulatory Requirements and Analytical Challenges. Available on: https:\/\/www.pmda.go.jp\/files\/000264160.pdf. Accessed February 22, 2025."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:08:32Z","timestamp":1750025312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"alternative-id":["S0928098725001344"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107135","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NDMA in macrolides: GC-MS\/MS method for its detection and study of its formation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107135"}}